Stunning amber fossil reveals ‘Last of Us'-type fungus likely lived alongside dinosaurs
The insect, along with a second specimen of a young ant infected with a similar fungus, are two of the oldest examples of a bizarre natural phenomenon that involves fungal parasites hijacking the bodies of their hosts before ultimately killing them.
'Amber gives us this opportunity to visualize the ancient ecological relationships preserved in fossils,' said Yuhui Zhuang, a doctoral student at the Institute of Paleontology at Yunnan University in southwestern China.
'Overall, these two fossils are very rare, at least among the tens of thousands of amber specimens we've seen, and only a few have preserved the symbiotic relationship between fungi and insects,' added Zhuang, the lead author of a study on the fossils published June 11 in the journal Proceedings of the Royal Society B: Biological Sciences.
Zhuang and his colleagues named two previously unknown species of ancient fungi of the genus Ophiocordyceps from their research on the amber, which involved using optical microscopes to study the tiny pieces of amber and micro-computed tomography to make 3D images of the fungi-infected insects. They found the first, named Paleoophiocordyceps gerontoformicae, on the ant and the second, Paleoophiocordyceps ironomyiae, on the fly.
Some Ophiocordyceps species that prey on ant species today are known as 'zombie-ant fungi' because the fungal parasite can manipulate the behavior of its hosts for its own benefit. The phenomenon inspired the video game behind the HBO TV show 'The Last of Us.' HBO shares a parent company, Warner Bros. Discovery, with CNN.
'The discovery of these two fossils suggests that terrestrial ecosystems were already very complex, and that Ophiocordyceps, in particular, may have begun to act as 'predators' of insects in the Cretaceous period, regulating the populations of certain groups,' Zhuang said via email.
Today, parasitic fungi, also known as entomopathogenic fungi, infect a wide range of insect groups, including ants, flies, spiders, cicadas and beetles, according to London's Natural History Museum.
In the case of carpenter ants, the spore of the Ophiocordyceps fungus lands on the head of an ant, enters its brain through a weak area in the insect's exoskeleton and takes control of the ant to facilitate its spread, said Conrad Labandeira, senior scientist and curator of fossil arthropods at the Smithsonian Museum of Natural History in Washington, DC, who wasn't involved in the study.
Paleoophiocordyceps likely zombified its hosts in similar ways, according to Labandeira.
'It appears that ants, for some reason, were targeted early for zombification, and currently are the major recipients of this parasitoid fungus,' Labandeira said. He added that flies are only rarely affected by these parasitic fungi today, making a fossilized example particularly interesting.
The species of fungus that infected the prehistoric ant may be an ancestor of zombie-ant fungi, and thus likely controlled its host's body in similar ways, said study coauthor João Araújo, mycology curator and assistant professor at the Danish Natural History Museum. Very few specimens of ancient parasitic fungi have been discovered, so little is known about their evolution.
The two insects were likely killed by the fungi before getting trapped in the sticky tree resin that ultimately forms amber, said Araújo, noting that most entomopathogenic fungi kill their hosts to produce the fruiting body.
This lost parasite diversity had a significant role in shaping the planet we live on today, said Phil Barden, an associate professor at New Jersey Institute of Technology's department of biological sciences, who has worked on amber fossils.
'Even as we find a remarkable diversity of organisms entombed in amber, it's important to remember that we really do only capture the smallest glimpse. For any given fossil ant or beetle, we can imagine all of the parasites, fungus, and bacteria that such insects support,' Barden, who wasn't involved in the new study, said via email.
It was 'fascinating to see some of the strangeness of the natural world that we see today was also present at the height of the age of the dinosaurs,' said study coauthor Edmund Jarzembowski, a professor and associate scientist at London's Natural History Museum.
The fossil is the latest to emerge from Myanmar's rich amber fields.
While amber fossils have been some of paleontology's most exciting finds in recent years, ethical concerns about the provenance of amber from the civil war-torn region have emerged.
Zhuang said the fossils were sourced from Myanmar's amber markets. The study noted that the specimens were acquired before 2017 and, to the authors' knowledge, were not involved in armed conflict or ethnic strife.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
15 hours ago
- Medscape
Stapokibart Improves Rhinosinusitis With Nasal Polyps
Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from 179 individuals. Biologics are now more commonly used as treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), and monoclonal antibodies have emerged as significantly more effective than other biologics for these patients, wrote Shen Shen, MS, of Capital Medical University, Beijing, China, and colleagues. In a study known as CROWNS-2 published in JAMA , the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 mg subcutaneously) or a placebo injection every 2 weeks for 24 weeks. All participants also received 100 μg of mometasone furoate per nostril once a day as background treatment before and during the study. The co-primary endpoints were changes in nasal polyp score and nasal congestion score from baseline to 24 weeks in the study population overall and in the subgroup with eosinophilic chronic rhinosinusitis with nasal polyps. The 24-week double-blind period was followed by an open-label extension to 52 weeks. Key secondary endpoints included the percentage of patients who achieved improvement of 1 point or more on nasal polyp scores and 2 points or more on nasal polyp scores. The final analysis included 90 individuals in the stapokibart group and 89 in the placebo group. The mean age of the study population was 45 years, and approximately one third were women. The mean duration of CRSwNP was 6.0 years, and 139 patients (77.7%) had eosinophilic CRSwNP. Study Outcomes Compared with placebo patients at 24 weeks, patients in the stapokibart group had a significant reduction in polyp size, with least-squares mean (LSM) changes in nasal polyp score from baseline of -2.6 and -0.3 points, respectively ( P < .001). Similarly, patients in the stapokibart group had a significantly greater LSM change in nasal congestion score from baseline to week 24 than those in the placebo group (-1.2 points vs -0.5 points, respectively; P < .001). Nearly all of the patients treated with stapokibart (96.5%) had a reduction in nasal polyp score of at least 1 point, and 89.5% had a reduction of at least 2 points after 52 weeks. The improvements in both primary endpoints were even greater among patients with eosinophilia, with an LSM change of -3.0 vs -0.04 for nasal polyp scores and -1.3 vs -0.5 for nasal congestion scores in stapokibart vs placebo patients, respectively. The overall incidence of adverse events in the first 24 weeks of the study was similar for the stapokibart and placebo groups. The most common adverse events were upper respiratory tract infections, COVID-19, and unconfirmed but suspected COVID-19. Serious adverse events were rare and similar between the stapokibart and placebo groups (2.2% vs 1.1%). However, higher rates of arthralgia and hyperuricemia were reported with stapokibart than with placebo (7.8% vs 0% and 5.6% vs 1.1%, respectively). The findings were limited by several factors, including the lack of data on aspirin-exacerbated respiratory disease, the small numbers of patients, and the inclusion only of patients in China, the researchers noted. However, the results support the potential of stapokibart to reduce nasal polyp size and symptom severity in adults with severe CRSwNP, they concluded. Emergence of Endotyping The significant reduction in polyp score was the study's most notable finding, according to an accompanying editorial. 'The emergence of biologic therapies for chronic rhinosinusitis with nasal polyps has brought the concept of inflammatory endotyping to the forefront of this condition,' wrote Michael P. Platt, MD, of Boston University Chobanian & Avedisian School of Medicine, Boston; Stacey T. Gray, MD, of Harvard Medical School, Boston; and Anju T. Peters, MD, of Northwestern University Feinberg School of Medicine, Chicago. The current study included a majority of individuals with eosinophilic CRSwNP, and the successful reduction in polyp size was based on correct identification of this T2 endotype, as stapokibart targeted T2 inflammation, they said. However, choosing the appropriate biologic therapy for uncontrolled CRSwNP with nasal polyps also requires consideration of other comorbid atopic diseases and disease pathogenesis, with shared decision-making, they added. Tuning in to Eosinophilia 'Currently, three biologics are approved for CRSwNP in the US, with additional agents likely to follow,' said Michael S. Blaiss, MD, an allergist and clinical professor at the Medical College of Georgia at Augusta University, Augusta, Georgia, in an interview. 'What distinguishes this trial is that the investigators specifically defined and studied eosinophilic CRSwNP,' said Blaiss, who was not involved in the study. 'In this subgroup, the biologic demonstrated significant efficacy, providing important data for this population of CRSwNP sufferers,' he said. The study findings were not unexpected, as stapokibart has a similar mechanism of action to dupilumab, said Blaiss. 'Both target the IL-4Rα [interleukin-4 receptor subunit alpha] receptor, albeit at different binding sites and affinities, and dupilumab is already FDA-approved for CRSwNP, so efficacy was expected,' he said. 'However, safety findings warrant attention,' he emphasized. The significantly greater occurrence of arthralgia and hyperuricemia in stapokibart vs placebo patients deserves further evaluation in larger and longer studies, Blaiss said. 'If approved, this biologic would provide an additional treatment option for patients with moderate to severe CRSwNP,' Blaiss told Medscape Medical News . However, its advantages over currently available biologics remain unknown, as the dosing schedule of every 2 weeks does not improve convenience, he noted. 'Head-to-head comparative studies are needed, similar to the recent dupilumab vs omalizumab trial in CRSwNP, to determine whether one biologic is clinically superior,' said Blaiss. 'Furthermore, evaluation in noneosinophilic CRSwNP is necessary, as the present study included too few patients in this subgroup for meaningful statistical analysis,' he added.
Medscape
19 hours ago
- Medscape
Rivaroxaban or Combo Therapy: A Winner for All Ages?
TOPLINE: In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy reduced the risks for major cardiovascular events (MACE) and major bleeding across all adult age groups. METHODOLOGY: Researchers performed a post hoc analysis of data from the AFIRE trial, conducted in Japan, to assess the age-stratified effects of rivaroxaban monotherapy vs treatment with rivaroxaban plus an antiplatelet agent. The analysis included 2215 patients (mean age, 74.3 years; 79.1% men) with AF and stable CAD more than 1 year after revascularization or angiographically confirmed CAD that did not need revascularization. Patients were randomly assigned to 10 mg or 15 mg of rivaroxaban monotherapy, depending on creatinine clearance, or combination therapy involving rivaroxaban plus aspirin or a P2Y12 inhibitor (at the physician's discretion). The patients were stratified into four age groups: younger than 70 years, 70-74 years, 75-79 years, and 80 years or older. The primary efficacy endpoint was MACE, defined as a composite of stroke, myocardial infarction, systemic embolism, unstable angina requiring revascularization, or death; the primary safety endpoint was major bleeding. The patients were followed for up to 45 months. TAKEAWAY: Across the age spectrum, rivaroxaban alone matched combination therapy for reducing the risks for MACE and major bleeding. However, rivaroxaban monotherapy, compared with combination therapy, was associated with a more pronounced reduction in the risk for MACE among patients aged 80 years or older (hazard ratio [HR], 0.61; 95% CI, 0.40-0.93) and a more pronounced reduction in the risk for major bleeding among those younger than 70 years (HR, 0.23; 95% CI, 0.06-0.79). IN PRACTICE: 'Although the present study did not clarify the factors involved, it is important to reaffirm that rivaroxaban monotherapy effectively reduces net adverse clinical events, which comprehensively include both thrombotic and hemorrhagic events, across a wide age range, even in older patients,' the researchers reported. SOURCE: This study was led by Junichi Yamaguchi, MD, PhD, of the Department of Cardiology at Tokyo Women's Medical University in Tokyo, Japan. It was published online on August 13, 2025, in JAMA Cardiology. LIMITATIONS: The open-label design of the trial may have introduced bias. As a post hoc analysis, this study was underpowered, and differences between the two arms may have been missed due to small sample size. The antiplatelet agent was chosen by the treating physician and was not standardized. DISCLOSURES: This study received support from the Japan Cardiovascular Research Foundation through a contract with Bayer Yakuhin, Ltd. Several authors reported receiving grants, personal fees, and endowments from multiple sources, including Bayer, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Abbott, among others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
20 hours ago
- Yahoo
Breastfeeding could help prevent early puberty in girls and boys, South Korean study finds
Girls and boys who were exclusively breastfed during their first four to six months showed a reduced risk of early puberty, according to a large new study from South Korea that Canadian doctors say could apply here. The study, published in Monday's issue of JAMA Network Open, looked back at the diets and development of more than 300,000 children from 2007 to 2020, based on data from checkups at four to six months of age and before six years. Worldwide, puberty has increasingly begun earlier in kids. Called "central precocious puberty," it's linked to an increased risk of health problems in adulthood, like heart disease, cancer and diabetes, as well as mental health issues like depression and anxiety. The researchers believe that kids who are exclusively breastfed are less likely to develop childhood obesity, a major predisposing factor of early puberty. However, experts note that many mothers face challenges in breastfeeding, which they say should be addressed on a structural level. "The take-home message should be, for parents or to-be parents, that breastfeeding has multiple beneficial health effects for their children," said Dr. Sonia Anand, associate vice-president of global health at McMaster University, who was not involved in the study. "And the second message is it is not always easy to do." Long-term benefits of breastfeeding About 46 per cent of the babies in the South Korean study were exclusively breastfed, more than a third had formula and nearly 20 per cent had both. "The idea is that breastfed kids are less likely to have extra weight and that's the mechanism whereby they're more protected from developing early puberty," said Dr. Kaberi Dasgupta, a professor of medicine and physician scientist at the McGill University Health Centre, who also was not involved in the study. Boys who were fed just formula had a 16 per cent increased risk of early puberty compared with their peers who were only fed breast milk, the researchers found. For exclusively formula-fed girls, the association jumped to 60 per cent. For mixed-fed boys, it was 14 per cent higher, compared with 45 per cent for girls. The researchers noted some caveats to their study. The participants self-reported how long they breastfed their children, for example. It also couldn't include genetic factors like maternal age of puberty. The early part of life is a key time, as that's when a lot of disease risk is set, wrote doctors Lin Yang and Shengxu Li. Though they weren't involved in the study, they wrote an accompanying journal commentary. "Disease starts early, so should its prevention," they said. Dasgupta says there's no reason to think the findings would be different in Canada. Preventing early puberty can also help kids in other ways, she adds. "The earlier your puberty, the shorter you may become," she said. "There's also the stigma around having early signs of being an adult when you're still a kid. Other kids may tease you." Supporting mothers instead of shaming Yang and the researchers say that instead of putting pressure on new moms, a society-wide approach is important. That includes stronger parental leave policies, workplace accommodations like a private space to breastfeed and lactation support services. "I think policy support, raised awareness, as well as creating the environment for women to be able to [breastfeed] is very important," Yang told CBC News. Sleep patterns, physical activity levels and screen time could also be increasing childhood obesity and early puberty rates, Yang and Li wrote in their commentary, as well as environmental pollutants like endocrine disruptors, though she acknowledged there isn't good data on that. In Canada, about 91 per cent of parents start out breastfeeding. About 38 per cent of parents breastfed exclusively for at least six months, Statistics Canada reported in 2024. Of those who stopped before six months, reasons included not having enough breast milk, finding breastfeeding difficult and the child weaning themself off of it. "I think the wrong takeaway and the wrong approach is to shame mothers who try to breastfeed but can't continue," Anand said. Breastfeeding is one factor among many that can influence weight gain in kids. Lifestyle choices like limiting fast food and cooking with more vegetables and lean proteins can also help prevent childhood obesity, doctors say. While the South Korean study doesn't prove that formula feeding causes early puberty, the researchers had a robust data set and the associations are plausible, she said. Anand's own research demonstrated early breastfeeding and for at least six months was associated with lower levels of excess body fat in children at age three. She says she'd like to see other large studies show similar findings to the South Korean to nail down cause and effect. Studies looking at how genes are tied to precocious puberty could also help, she said.
